Redeye: Devyser Q3 - All eyes on Q4
Redeye returns with a more in-depth take on Devyser’s Q3 report. While sales disappointed, we are confident it is just a temporary setback and we believe that by next quarter, the company will demonstrate that sales will continue to progress handsomely.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/